The purpose of this study is to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle) in subjects with solid tumors

Inclusion Criteria

• Subjects with histologically and/or cytologically diagnosis of solid tumor
• Subjects with solid tumor which is resistant to standard anti-tumor therapies, or which no appropriate treatment is available
• Subjects whose toxicity of previous treatment has recovered to Grade 1 or lower toxicity (except for alopecia)
• Subjects who completed previous anti-tumor therapy before at least 4 weeks
• Subjects who are 20 years or older
• Subjects with 0 to 1 of Performance Status
• Subjects agree to be hospitalized for DLT observation
• Subjects with adequate organ functions
• Males and females of childbearing potential must agree to use appropriate contraception from the agreement to 30 days after study drug administration.
• Agree to participate in this study in writing based on voluntary will

Exclusion Criteria

• Subjects with brain metastasis accompanying clinical symptoms or requiring treatment
• Subjects with the severe complication or disease history
• Subjects unable to take oral medication.
• Subjects being treated with drugs that strongly inhibit or induce CYP3A4 and that may be possibly used during this study.
• Scheduled for surgery during the projected course of the study.
• Positive for human immunodeficiency virus (HIV antibody) test or positive for hepatitis B surface (HBs antigen) or hepatitis C (HCV antibody) by serum test.
• Subjects who in the view of the investigator are not able to comply with this protocol because of psychiatric or physical diseases including alcoholism or drug addict
• Pregnant or nursing subjects
• Subjects who are participating in another clinical trial.

Until participants met discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent or up to 19 cycles (1 cycle = 28 days).